Find your next paid study

Duke UniversityNCT06983691

~$10 – $6,250

Estrogen-receptor-positive Breast CancerHER2/Neu-Negative Breast CancerAdvanced Breast Cancerv+1 more

Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+/HER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4/6 Inhibitor

Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negat…

Northwestern UniversityNCT06062498

~$10 – $6,250

Metastatic Breast CancerTriple Negative Breast CancerEstrogen-receptor-low Breast Cancer+1 more

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and n…

PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive Tumor+3 more

Kathy MillerNCT05846789

Phase 3

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib +…

Relay Therapeutics, Inc.NCT06982521

~$10 – $8,750

Phase 3

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlim…

Breast CancerMetastatic Breast CancerBreast Neoplasm+2 more

BriaCell Therapeutics CorporationNCT06072612

~$10 – $8,750

Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer

This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collect…

Metastatic Breast CancerLobular Breast Carcinoma

University of California, San FranciscoNCT05964504

~$10 – $675

Phase 1

Phase Ib Active Immunotherapy Trial (Expansion) With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine Emulsified in ISA 51 Adjuvant in Patients With Advanced Solid Tumors

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies a…

Metastatic Breast CancerHER2-positive Breast CancerEGFR Overexpression+2 more

Pravin T.P KaumayaNCT06414733

Breast CancerHER2-low Breast CancerMetastatic Breast Cancer+1 more

A Phase II Non-comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-negative (HER2-low or HER2-0) Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab …

Ana C Garrido-Castro, MDNCT06533826

Estrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more

A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)

The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrog…

Kristina A. FanucciNCT07222215

Observational

A Phase 2 Study of TheraBionic P1 Device for Patients With Metastatic Hormone Positive Breast Cancer Post Endocrine Therapy

The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer…

HER2-negative Breast CancerHormone Receptor Positive TumorAdvanced Breast Cancer+1 more

Barbara Ann Karmanos Cancer InstituteNCT07227831

Prospective Evaluation of Quality of Life in Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease

Central nervous system (CNS) metastases including breast cancer brain metastases (BCBMs) and leptomeningeal disease (LMD) are common affecting up to 30% of pat…

Breast Cancer, Quality of LifeBreast Cancer, MetastaticBreast Cancer, Metastatic Breast Cancer+2 more

University of California, San FranciscoNCT07659652

~$10 – $675

Breast CancerMetastatic Breast Cancer (MBC)

A Phase II Study Evaluating the Efficacy and Safety of Romosozumab as a Bone-Modifying Agent in Patients With Metastatic Breast Cancer to Bones and Osteoporosis With High Fracture Risk (REMOLD-Breast)

The researchers are doing this study to see if romosozumab is effective at helping with bone formation in people with metastatic breast cancer (MBC) that has s…